Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

NCT01325220 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Fragile X Syndrome

Interventions

DRUG: arbaclofen
DRUG: arbaclofen
DRUG: arbaclofen
DRUG: Placebo

Sponsor

Seaside Therapeutics, Inc.